Newsletter
Sign up for the Fund's newsletter and get the lastest news, calls and events
| Titel Sort descending | Periode | Program | |
|---|---|---|---|
| Development of a novel multi-targeted T-cell therapy product against HPV-induced cervical cancer | 2023 - 2026 | Industrial Researcher
|
|
|
Development of a novel multi-targeted T-cell therapy product against HPV-induced cervical cancer
Period
2023 - 2026
Region
Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
59.1 Invested
1.1 mill. Budget
1.8 mill. Vha. en banebrydende teknologi udviklet af prof. Sine Hadrup på DTU kan man i laboratoriet selektivt ekspandere de immunceller (T-celler), som, når de kommer tilbage i patienten, vil opspore og udrydde kræften. Sammen med Cbio A/S, der fokuserer på denne nye klasse af ’levende drugs’ er målet at udvikle en kurativ behandling imod senstadie livmoderhalskræft, som er klar til klinisk udvikling og derved bringe et nyt produkt på markedet i slut 2020erne til gavn for kvinder med denne kræftform.
Partners
Technical University of Denmark, CBio A/S People
Read more about the project
| |||
| Development of a novel platform for in vivo evaluation of blood brain barrier penetration of CNS-targeting drugs | 2021 - 2024 | Industrial Researcher
|
|
|
Development of a novel platform for in vivo evaluation of blood brain barrier penetration of CNS-targeting drugs
Period
2021 - 2024
Region
Region Hovedstaden Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
30.03 Invested
1.1 mill. Budget
3.6 mill. Partners
University of Copenhagen, MINERVA IMAGING ApS People
MINERVA IMAGING ApS
Read more about the project
| |||
| Development of a Novel Platform for Screening Interactions with Human Serum Albumin | 2017 - 2020 | Industrial Researcher
|
|
|
Development of a Novel Platform for Screening Interactions with Human Serum Albumin
Period
2017 - 2020
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
41.71 Invested
1.1 mill. Budget
2.6 mill. Partners
Aarhus University, Novo Nordisk A/S People
Novo Nordisk A/S
Read more about the project
| |||
| Development of a novel point-of-care device to measure inflammation (suPAR) in fingerprick blood | 2021 - 2023 | Innobooster
|
|
|
Development of a novel point-of-care device to measure inflammation (suPAR) in fingerprick blood
Period
2021 - 2023
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
2.8 mill. Budget
8.6 mill. Partners
ViroGates A/S People
VIROGATES A/S
Read more about the project
| |||
| Development of a peptide-based CD133-targeting optical probe for image-guided cancer surgery | 2020 - 2023 | Industrial Researcher
|
|
|
Development of a peptide-based CD133-targeting optical probe for image-guided cancer surgery
Period
2020 - 2023
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
1.2 mill. Budget
1.2 mill. Partners
University of Copenhagen, FluoGuide A/S People
FluoGuide A/S
Read more about the project
| |||
| Development of a platform for isolation of circulating tumor cells to improve early cancer detection and diagnosis. | 2017 - 2020 | Industrial Researcher
|
|
|
Development of a platform for isolation of circulating tumor cells to improve early cancer detection and diagnosis.
Period
2017 - 2020
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
22.79 Invested
1.1 mill. Budget
4.7 mill. Partners
University of Copenhagen, VarCT Diagnostics ApS People
VarCT Diagnostics ApS
Read more about the project
| |||
| Development of a Prophylactic Vaccine against Hepatitis C Virus | 2023 - 2024 | Innoexplorer
|
|
|
Development of a Prophylactic Vaccine against Hepatitis C Virus
Period
2023 - 2024
Region
Program
Innoexplorer Area
Ikke defineret Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
HVIDOVRE HOSPITAL People
Read more about the project
| |||
| Development of a Prophylactic Vaccine Against Hepatitis C Virus | 2019 - 2020 | Innoexplorer
|
|
|
Development of a Prophylactic Vaccine Against Hepatitis C Virus
Period
2019 - 2020
Region
Region Hovedstaden Program
Innoexplorer Area
Biotek, Medico og Sundhed Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
HVIDOVRE HOSPITAL People
HVIDOVRE HOSPITAL
Read more about the project
| |||
| Development of a Prophylactic Vaccine Against Hepatitis C Virus | 2021 - 2022 | Innoexplorer
|
|
|
Development of a Prophylactic Vaccine Against Hepatitis C Virus
Period
2021 - 2022
Region
Region Hovedstaden Program
Innoexplorer Area
Ikke defineret Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
HVIDOVRE HOSPITAL People
HVIDOVRE HOSPITAL
Read more about the project
| |||
| Development of a Raman spectroscopy based control system for the U-Loop fermentor | 2016 - 2019 | Industrial Researcher
|
|
|
Development of a Raman spectroscopy based control system for the U-Loop fermentor
Period
2016 - 2019
Region
Region Sjælland Program
Erhvervsforsker Area
Produktion, Materialer, Digitalisering og IKT Investment
Percentage
40.67 Invested
1.1 mill. Budget
2.6 mill. Partners
Technical University of Denmark, UNIBIO A/S People
UNIBIO A/S
Read more about the project
| |||
| Development of a screening kit for quality control of enzyme production | 2016 - 2016 | Innobooster
|
|
|
Development of a screening kit for quality control of enzyme production
Period
2016 - 2016
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33.24 Invested
495.950 Budget
1.5 mill. Partners
GLYCOSPOT IVS People
GlycoSpot ApS
Read more about the project
| |||
| Development of a Single Cell RNA Sequencing platform for Bacteria to Delineate Antibiotic Hetero-resistance | 2023 - 2026 | Industrial Researcher
|
|
|
Development of a Single Cell RNA Sequencing platform for Bacteria to Delineate Antibiotic Hetero-resistance
Period
2023 - 2026
Region
Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
60.7 Invested
1.1 mill. Budget
1.8 mill. Stafylokok-infektioner bliver ofte fejldiagnosticeret. Dette kan skyldes hetero-resistens hvor en bakteriepopulation udtrykker forskellige niveauer af resistens. I dag bliver subpopulationer af resistente bakterier sjældent opdaget under diagnostikken, hvilket kan resultere i fatal fejlbehandling. Derfor vil vi udforske denne niche kommercielt ved at udvikle en molekylær enkelt celle sekventeringsplatform til bakterielt RNA og hermed muliggøre udvikling af nøjagtige diagnostiske tests.
Partners
University of Copenhagen, AMPLEXA GENETICS A/S People
Read more about the project
| |||
| Development of a single photon source at telecom wavelength | 2024 - 2027 | Industrial Researcher
|
|
|
Development of a single photon source at telecom wavelength
Period
2024 - 2027
Region
Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
44.15 Invested
1.1 mill. Budget
2.4 mill. Sparrow Quantum (SQ) er en førende udbyder af enkelt-foton-kilder ved 950 nm. Virksomheden har leveret til forskningsgrupper og kvantecomputerudviklere, og vil nu udvide sin produktportefølje for at kunne imødekomme kvantekommunikationsindustrien. For at træde ind på dette marked er en effektiv deterministisk kilde til højkvalitets enkeltfotoner ved 1310 nm (O-båndet), afgørende. Projektet sigter mod at udvikle en sådan kilde og derved spille en afgørende rolle i kvantekommunikationsmarkedet.
Partners
University of Copenhagen, Sparrow Quantum ApS People
Read more about the project
| |||
| Development of a Sustainable Emulsification Device | 2024 - 2026 | Innobooster
|
|
|
Development of a Sustainable Emulsification Device
Period
2024 - 2026
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
1.4 mill. Budget
4.1 mill. Partners
Inmold A/s People
Read more about the project
| |||
| Development of a sustainable fermentation process for high value lipoic acid | 2018 - 2020 | Innobooster
|
|
|
Development of a sustainable fermentation process for high value lipoic acid
Period
2018 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Biotek, Medico og Sundhed Investment
Percentage
32.9 Invested
4.8 mill. Budget
14.7 mill. Partners
Biosyntia ApS People
BIOSYNTIA ApS
Read more about the project
| |||